Literature DB >> 23122052

Type I interferon response and innate immune sensing of cancer.

Mercedes B Fuertes1, Seng-Ryong Woo, Byron Burnett, Yang-Xin Fu, Thomas F Gajewski.   

Abstract

Unexpectedly, many cancers appear to induce a spontaneous adaptive T cell response. The presence of a T cell infiltrate has been linked to favorable clinical outcome in multiple cancer types. However, the innate immune pathways that bridge to an adaptive immune response under sterile conditions are poorly understood. Recent data have indicated that tumors can induce type I interferon (IFN) production by host antigen-presenting cells (APCs), which is required for a spontaneous T cell response in vivo. The innate immune sensing pathways that trigger type I IFN production are being elucidated. Host type I IFNs are also required for optimal therapeutic efficacy with radiation. This recently uncovered role for host type I IFNs for antitumor immunity has important fundamental and clinical implications.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23122052      PMCID: PMC3565059          DOI: 10.1016/j.it.2012.10.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  57 in total

1.  Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation.

Authors:  Julie M Curtsinger; Javier O Valenzuela; Pujya Agarwal; Debra Lins; Matthew F Mescher
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

2.  Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.

Authors:  Agnes Le Bon; Clare Thompson; Elisabeth Kamphuis; Vanessa Durand; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

3.  Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection.

Authors:  Colin Havenar-Daughton; Ganesh A Kolumam; Kaja Murali-Krishna
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

4.  Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses.

Authors:  Katja Fink; Karl S Lang; Nataly Manjarrez-Orduno; Tobias Junt; Beatrice M Senn; Martin Holdener; Shizuo Akira; Rolf M Zinkernagel; Hans Hengartner
Journal:  Eur J Immunol       Date:  2006-08       Impact factor: 5.532

5.  Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

Authors:  Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

6.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

7.  Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Authors:  Agnes Le Bon; Vanessa Durand; Elisabeth Kamphuis; Clare Thompson; Silvia Bulfone-Paus; Cornelia Rossmann; Ulrich Kalinke; David F Tough
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

8.  Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection.

Authors:  Elizabeth S Coro; W L William Chang; Nicole Baumgarth
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

9.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection.

Authors:  Ganesh A Kolumam; Sunil Thomas; Lucas J Thompson; Jonathan Sprent; Kaja Murali-Krishna
Journal:  J Exp Med       Date:  2005-08-29       Impact factor: 14.307

10.  Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation.

Authors:  Yasutaka Okabe; Kohki Kawane; Shizuo Akira; Tadatsugu Taniguchi; Shigekazu Nagata
Journal:  J Exp Med       Date:  2005-11-21       Impact factor: 14.307

View more
  136 in total

1.  Finding a fairy in the forest: ELF4, a novel and critical element of type I interferon responses.

Authors:  Attila Szabo; Eva Rajnavolgyi
Journal:  Cell Mol Immunol       Date:  2014-03-24       Impact factor: 11.530

2.  C/EBPβ regulates the M2 transcriptome in β-adrenergic-stimulated macrophages.

Authors:  Donald M Lamkin; Shreyesi Srivastava; Karen P Bradshaw; Jenna E Betz; Kevin B Muy; Anna M Wiese; Shelby K Yee; Rebecca M Waggoner; Jesusa M G Arevalo; Alexander J Yoon; Kym F Faull; Erica K Sloan; Steve W Cole
Journal:  Brain Behav Immun       Date:  2019-05-24       Impact factor: 7.217

Review 3.  New perspectives on type I IFNs in cancer.

Authors:  Thomas F Gajewski; Leticia Corrales
Journal:  Cytokine Growth Factor Rev       Date:  2015-01-07       Impact factor: 7.638

4.  Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Authors:  Stefani Spranger; Ayelet Sivan; Leticia Corrales; Thomas F Gajewski
Journal:  Adv Immunol       Date:  2016-01-22       Impact factor: 3.543

5.  Combining activatable nanodelivery with immunotherapy in a murine breast cancer model.

Authors:  Azadeh Kheirolomoom; Matthew T Silvestrini; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Spencer K Tumbale; Josquin Foiret; Neil E Hubbard; Alexander D Borowsky; Katherine W Ferrara
Journal:  J Control Release       Date:  2019-04-09       Impact factor: 9.776

6.  Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma.

Authors:  Liliana M E Finocchiaro; Chiara Fondello; María L Gil-Cardeza; Úrsula A Rossi; Marcela S Villaverde; María D Riveros; Gerardo C Glikin
Journal:  Hum Gene Ther       Date:  2015-05-26       Impact factor: 5.695

Review 7.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

8.  Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses.

Authors:  Ewa M Kosciuczuk; Swarna Mehrotra; Diana Saleiro; Barbara Kroczynska; Beata Majchrzak-Kita; Pawel Lisowski; Caroline Driehaus; Anna Rogalska; Acara Turner; Thomas Lienhoop; David Gius; Eleanor N Fish; Athanassios Vassilopoulos; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2018-11-28       Impact factor: 5.157

9.  Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Joseph Conlon; Dara L Burdette; Shruti Sharma; Numana Bhat; Mikayla Thompson; Zhaozhao Jiang; Vijay A K Rathinam; Brian Monks; Tengchuan Jin; T Sam Xiao; Stefanie N Vogel; Russell E Vance; Katherine A Fitzgerald
Journal:  J Immunol       Date:  2013-04-12       Impact factor: 5.422

Review 10.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.